drugset / Trial / NCT00064376
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
Open-labelTreatment
Summary
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
Timeline
- Start
- 2003-05
- Primary completion
- 2005-11
- Completion
- 2005-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paricalcitol | Other / unclassified | — | Oral |